⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15912312 | 0.76 | KDM4E (0.30) | — | |
| SCHEMBL27416749 | 0.74 | — | — | |
| SCHEMBL993543 | 0.72 | — | — | |
| SCHEMBL17904739 | 0.67 | — | — | |
| SCHEMBL25908908 | 0.67 | — | — | |
| SCHEMBL6737169 | 0.63 | — | — | |
| SCHEMBL12032920 | 0.61 | — | — | |
| SCHEMBL11802553 | 0.51 | HRH4 (0.34) | — | |
| SCHEMBL12890926 | 0.48 | CYP1A2 (0.31) | — | |
| SCHEMBL170393 | 0.48 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11873298-B2 | Compounds and uses thereof | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-16 | — | — | US | disclosed |
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-11692043-B2 | Peptidomimetic compounds and antibody-drug conjugates thereof | MEDIMMUNE LIMITED (GB) | 2023-07-04 | — | — | US | disclosed |
| WO-2023114379-A1 | PLPRO INHIBITORS | HUAHAI US INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| EP-3822263-A1 | BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2021-05-19 | — | — | EP | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-9676802-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170114046-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARM INC (US) | 2017-04-27 | — | — | US | disclosed |
| US-20160310611-A1 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | GENENTECH INC. (US) | 2016-10-27 | — | — | US | disclosed |
| US-20160009723-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-01-14 | — | — | US | disclosed |
| US-20100316607-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| US-20100234343-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7705158-B2 | Inhibitors of ion channels | ICAGEN, INC. (US) | 2010-04-27 | — | — | US | disclosed |
| US-20100041707-A1 | INHIBITORS OF ION CHANNELS | ICAGEN, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-7615569-B2 | Inhibitors of ion channels | ICAGEN, INC. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090197880-A1 | ANTI-VIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090074717-A1 | Anti-viral compounds, compositions, and methods of use | GLAXOSMITHKLINE LLC | 2009-03-19 | — | — | US | disclosed |
| US-7271179-B2 | Inhibitors of JAK protein kinase | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070135493-A1 | INHIBITORS OF ION CHANNELS | ICAGEN (US) | 2007-06-14 | — | — | US | disclosed |
| US-20070078145-A1 | INHIBITORS OF ION CHANNELS | ICAGEN (US) | 2007-04-05 | — | — | US | disclosed |